A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Eligibility criteria
Qualifiers
Signed Informed Consent Form(s)
Ability to comply with all the study-related procedures, in the investigator's judgement
Age 18 years or older
ECOG performance Status of 0, 1, or 2 [Appendix 2]
Disqualifiers
Inability to comply with all the study-related procedures, in the investigator's judgement.
FL grade 3B or transformed FL
Patients not meeting criteria for systemic therapy as outlined in section 6.1 and Appendix 4
Patients unfit for chemoimmunotherapy for reasons including, but not limited to, advanced age and medical comorbidities
Trial design
Treatments tested in this trial
- Mosunetuzumab
- Zanubrutinib
Treatment groups
152 Participants
are divided into 2 treatment groupsLocations
9Georgetown University (Data Collection Only)20007, Washington D.C.District of Columbia, United States
Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities07920, Basking RidgeNew Jersey, United States
Hackensack Meridian Health (Data collection only)07601, HackensackNew Jersey, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)07748, MiddletownNew Jersey, United States
Sponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Source ClinicalTrials.gov